News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adimab LLC. Announces New Antibody Discovery Program with Gilead Sciences, Inc. (GILD) and Initiates First Bispecific Antibody Collaboration



4/19/2012 10:05:20 AM

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human therapeutic antibodies, today announced the initiation of two new independent research collaborations. Adimab and Gilead Sciences, Inc. (Nasdaq:GILD) of Foster City, CA, have initiated a research collaboration to identify therapeutic antibodies against two targets selected by Gilead. In addition, Adimab has expanded one of its current partnerships to initiate a new project in the area of bispecific antibodies. Adimab today announced the achievement of several technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES